DexCom Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view top-rated stocks.

Wall Street analysts have given DexCom a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DexCom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Thursday, July 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, April, 29th. The medical device company reported $0.33 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.31 by $0.02. The medical device company had revenue of $505 million for the quarter, compared to analysts' expectations of $482.67 million. DexCom had a net margin of 25.36% and a trailing twelve-month return on equity of 17.86%.
View DexCom's earnings history.

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 82.2% and is now trading at $459.92.
View which stocks have been most impacted by COVID-19.

DexCom issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $2.26 billion-$2.36 billion, compared to the consensus revenue estimate of $2.32 billion.

15 equities research analysts have issued 12-month target prices for DexCom's stock. Their forecasts range from $380.00 to $525.00. On average, they anticipate DexCom's share price to reach $465.60 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for DexCom or view top-rated stocks among Wall Street analysts.

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), STERIS (STE), Insulet (PODD) and Abiomed (ABMD).
View all of DXCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include TCW Group Inc. (0.30%), Marathon Asset Management LLP (0.14%), Scout Investments Inc. (0.06%), Gradient Investments LLC (0.02%), Vancity Investment Management Ltd (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Vancity Investment Management Ltd, Palisade Asset Management LLC, Patten & Patten Inc. TN, State of Alaska Department of Revenue, and New England Research & Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Bridgette P Heller, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, TCW Group Inc., CHICAGO TRUST Co NA, Gradient Investments LLC, IFM Investors Pty Ltd, Scout Investments Inc., Raymond James Trust N.A., and New Mexico Educational Retirement Board.
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $459.92.

DexCom has a market capitalization of $44.48 billion and generates $1.93 billion in revenue each year. The medical device company earns $493.60 million in net income (profit) each year or $3.10 on an earnings per share basis.

DexCom employs 6,400 workers across the globe.

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

DexCom was founded in 1999.

The official website for DexCom is www.dexcom.com.

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]